CoChat
Sign Up
Cited by 557Sleep and related disordersCancer survivorship and careSleep and Work-Related Fatigue

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Prevalence, Demographics, and Psychological Associations of Sleep Disruption in Patients With Cancer: University of Rochester Cancer Center–Community Clinical Oncology Program

Open access
Palesh, Oxana G., Roscoe, Joseph A., Mustian, Karen M., Roth, Thomas, Savard, Josée, Ancoli-Israel, Sonia, Heckler, Charles, Purnell, Jason Q., Janelsins, Michelle C., Morrow, Gary R.·2010·Journal of Clinical Oncology
DOI 10.1200/jco.2009.22.5011PMC PMC2815717
Open this paper in CoChat — free account

Abstract

Purpose: Sleep disruption is prevalent in patients with cancer and survivors, but the prevalence of insomnia, a distressing sleep disorder, in these populations has yet to be determined in large-scale studies. Patients and Methods: A total of 823 patients with cancer receiving chemotherapy (mean age, 58 years; 597 female patients) reported on sleep difficulties in a prospective study. Results: During day 7 of cycle 1 of chemotherapy, 36.6% (n = 301) of the patients with cancer reported insomnia symptoms, and 43% (n = 362) met the diagnostic criteria for insomnia syndrome. Patients with cancer younger than 58 years were significantly more likely to experience either symptoms of insomnia or insomnia syndrome (χ 2= 13.6; P = .0002). Patients with breast cancer had the highest number of overall insomnia complaints. A significant positive association was found between symptoms of insomnia during cycles 1 and 2 of chemotherapy (ϕ = .62, P < .0001), showing persistence of insomnia during the first two cycles of chemotherapy. Sixty percent of the patient sample reported that their insomnia symptoms remained unchanged from cycle 1 to cycle 2. Those with insomnia complaints had significantly more depression and fatigue than good sleepers (all P < .0001). Conclusion: The proportions of patients with cancer in this sample reporting symptoms of insomnia and meeting diagnostic criteria for insomnia syndrome during chemotherapy are approximately three times higher than the proportions reported in the general population. Insomnia complaints persist throughout the second chemotherapy cycle for the majority of patients with cancer in this study. Insomnia is prevalent, underrecognized, undermanaged, and understudied among patients with cancer receiving chemotherapy.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.2009.22.5011

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Research works printed but not linked: 4

  1. Roth T, 2007, J Clin Sleep Med, 3, S7
  2. Balter MB, 1992, J Clin Psychiatry, 53, 34
  3. Redwine L, 2000, J Clin Endocrinol Metab, 85, 3597
  4. B Tack: Dimensions and correlates of fatigue in older adults with rheumatoid arthritis [doctoral dissertation, nursing] 1991 San Francisco, CA University of California

Cited by

Sorted by citations

Items 201–300 of 557

Related

See all

Metadata

Authors
Palesh, O. G., Roscoe, J. A., Mustian, K. M., Roth, T., Savard, J., Ancoli-Israel, S., Heckler, C., Purnell, J. Q., Janelsins, M. C., & Morrow, G. R.
Affiliations
  • Henry Ford Hospital (US)
  • From the University of Rochester, Rochester, NY; Henry Ford Hospital, Detroit, MI; Université Laval, Quebec City, Quebec, Canada; University of California San Diego, San Diego, CA; and Washington University, St Louis, MO.
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2010-01-10
Volume
28
Issue
2
Pages
292-298
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2009.22.5011
PMC
PMC2815717
OpenAlex
W2130553178
Cited by
557
References
44
Citations by year
2026: 27 · 2025: 50 · 2024: 31 · 2023: 28 · 2022: 51 · 2021: 49 · 2020: 34 · 2019: 34 · 2018: 38 · 2017: 34 · 2016: 35 · 2015: 22 · 2014: 34 · 2013: 31 · 2012: 24
FWCI
24.55
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pfizer
  • Sanofi
  • American Society of Clinical Oncology
  • National Institutes of Health (5k07ca132916-05)
  • National Cancer Institute (1K07CA132916, CA 112035, K07CA132916., U10CA037420, R01CA112035, R25CA10618, U10-CA37420)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
Keywords
insomnia, sleep disruption, cancer patients, chemotherapy, insomnia prevalence, depression, fatigue, breast cancer, age differences, psychological distress, cancer survivors
MeSH terms
Age Factors, Aged, Antineoplastic Agents, Female, Humans, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Neoplasms, Sex Factors, Prevalence, Racial Groups

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review